Prof Sir Marc Feldmann : Discoverer and Pioneer of Anti-TNF Therapy
Co-Chairman, Kennedy Institute of Rheumatology, University of Oxford
University of Melbourne, Walter & Eliza Hall Institute, Kennedy Institute, University of Oxford.
Analysis of human rheumatoid synovium led to anti-TNF therapy, world’s biggest drug class, $36 billion annually.1
Knighted 2010; Fellow Royal Society, Fellow Australian Academy Science, Foreign Member National Academy of Sciences. Recipient: Lasker Award, Crafoord Prize, Canada-Gairdner Award, Paul Janssen Award, Ernst Schering Prize, European Inventor of year 2007, Companion Order of Australia. Centocor sale to J&J at $4.9 billion was due to anti-TNF (Remicade) developed by Sir Marc Feldmann.
Prof Lawrence Steinman : Pioneer of Tysabri for Multiple Sclerosis and Inflammatory Bowel Disease
Co-Chairman, Harvard Medical School, Prof Stanford University, Prof of Neurology and Pediatrics
Prof Stanford University, Prof of Neurology and Pediatrics.
Analysed human multiple sclerosis brain tissue to discover key role of integrins. Led to Natalizumab, highly effective treatment for MS and Inflammatory Bowel Diseases, sales $2 billion annually.
Member National Academy of Sciences, National Academy of Medicine.
Charcot Prize, Dystel Prize, Cerami Prize, Frederik Sasse Prize. Board Member of Centocor, sold to J&J for $4.9 billion. Founder, Board Member of Neurocrine, mkt cap $8 billion.2
Dr Jonathan Rothbard :
CEO and CSO, Director
Columbia University. Rockefeller University, NY.
Imperial Cancer Research Fund.
Founder CannBioRx Life Sciences.
Founder of Amylin. Sold to AstraZeneca and Bristol-Myers Squibb for $5.3 billion.5
Warning: Invalid argument supplied for foreach() in /home/cbrlifescience/public_html/wp-content/themes/cannbiorex_life_sciences/team.php on line 340